European journal of cancer (Oxford, England : 1990) · 2026
Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).
СтатьяКлиническое исследование I фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kanemura Hiroaki, Tanizaki Junko, Matsumoto Koji, Masuishi Toshiki, Isobe Taichi, Kenmotsu Hirotsugu, Sunakawa Yu, Shimizu Toshio, Chiba Yasutaka, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Hayashi Hidetoshi
Аннотация
BACKGROUND: Combination therapy with a human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI) and an anti-HER2 antibody-drug conjugate (ADC) for HER2-mutant solid tumors has not previously been investigated in a clinical trial. We here evaluated the safety and efficacy of the HER2-TKI mobocertinib together with the anti-HER2 ADC trastuzumab emtansine (T-DM1) in a phase I study.
PATIENTS AND METHODS: In part Ia of the study, dose-limiting toxicity (DLT) was evaluated with mobocertinib administered orally at 80, 120, or 160 mg/day and T-DM1 intravenously at 3.6 mg/kg every 3 weeks according to a 3 + 3 dose-escalation design. In part Ib, safety and efficacy were investigated with additional patients with HER2-mutant solid tumors.
RESULTS: In part Ia, three patients treated with mobocertinib at 80 mg did not experience DLT whereas three patients treated at 120 mg did. The recommended dose of the study treatment was therefore determined to be mobocertinib at 80 mg plus T-DM1 at 3.6 mg/kg. In part Ib, 22 patients with various solid tumor types were enrolled. Among all 28 patients, treatment-emergent adverse events of grade ≥ 3-most commonly, platelet count decreased, diarrhea, and hypokalemia-occurred in 21 individuals (75.0%), with all such events being manageable with appropriate supportive care, dose reduction, or treatment interruption. For the 21 evaluable patients in part Ib, the confirmed objective response rate and median progression-free survival were 28.6% and 3.3 months, respectively.
CONCLUSIONS: The combination of mobocertinib at 80 mg and T-DM1 at 3.6 mg/kg was found feasible and demonstrated potential efficacy for HER2-mutant solid tumors.
CLINICAL TRIAL INFORMATION: jRCT2051220070 and UMIN000054805.
PATIENTS AND METHODS: In part Ia of the study, dose-limiting toxicity (DLT) was evaluated with mobocertinib administered orally at 80, 120, or 160 mg/day and T-DM1 intravenously at 3.6 mg/kg every 3 weeks according to a 3 + 3 dose-escalation design. In part Ib, safety and efficacy were investigated with additional patients with HER2-mutant solid tumors.
RESULTS: In part Ia, three patients treated with mobocertinib at 80 mg did not experience DLT whereas three patients treated at 120 mg did. The recommended dose of the study treatment was therefore determined to be mobocertinib at 80 mg plus T-DM1 at 3.6 mg/kg. In part Ib, 22 patients with various solid tumor types were enrolled. Among all 28 patients, treatment-emergent adverse events of grade ≥ 3-most commonly, platelet count decreased, diarrhea, and hypokalemia-occurred in 21 individuals (75.0%), with all such events being manageable with appropriate supportive care, dose reduction, or treatment interruption. For the 21 evaluable patients in part Ib, the confirmed objective response rate and median progression-free survival were 28.6% and 3.3 months, respectively.
CONCLUSIONS: The combination of mobocertinib at 80 mg and T-DM1 at 3.6 mg/kg was found feasible and demonstrated potential efficacy for HER2-mutant solid tumors.
CLINICAL TRIAL INFORMATION: jRCT2051220070 and UMIN000054805.